Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0004 | Actinomycin D

Molecular Formula C62H86N12O16
Molecular Weight 1255.4
Structure
State solid
Protein binding 0.05
Half life 36 hours
Absorption poorly absorbed from gastrointestinal tract
Trade names Cosmegen
Description binds to DNA and inhibits RNA synthesis

L

L01DA01 Dactinomycin


[L01DA] Actinomycines


[L01D] CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES


[L01] ANTINEOPLASTIC AGENTS


[L] Antineoplastic and immunomodulating agents

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 317 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]


H350 (86.75%): May cause cancer [Danger Carcinogenicity]


H360 (86.44%): May damage fertility or the unborn child [Danger Reproductive toxicity]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P201, P202, P264, P270, P281, P301+P310, P308+P313, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
rat LD50 intraperitoneal 100ug/kg (0.1mg/kg) Acta Obstetrica et Gynaecologica Japonica, English Edition. Vol. 23, Pg. 219, 1976.
guinea pig LD50 unreported 330ug/kg (0.33mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 236, 1980.
mouse LD50 intraperitoneal 750ug/kg (0.75mg/kg) Cancer Treatment Reports. Vol. 61, Pg. 103, 1977.
rat LD50 intravenous 460ug/kg (0.46mg/kg) Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960.
mouse LD50 intravenous 1025ug/kg (1.025mg/kg) Antibiotiki. Vol. 16, Pg. 443, 1971.
cat LDLo intraperitoneal 75ug/kg (0.075mg/kg) Antibiotiki. Vol. 16, Pg. 443, 1971.
mouse LD50 subcutaneous 500ug/kg (0.5mg/kg) "Antibiotics: Origin, Nature, and Properties," Korzyoski, T., et al., eds., Washington, DC, American Soc. for Microbiology, 1978Vol. 2, Pg. 1268, 1978.
dog LDLo intravenous 160ug/kg (0.16mg/kg) National Technical Information Service. Vol. PB225-594,
bird - wild LD50 oral 1mg/kg (1mg/kg) Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983.
mouse LDLo intratracheal 1mg/kg (1mg/kg) Toxicology Letters. Vol. 30, Pg. 63, 1986.
mouse LD50 oral 13mg/kg (13mg/kg) Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960.
rabbit LD50 unreported 150ug/kg (0.15mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 236, 1980.
hamster LD50 unreported 600ug/kg (0.6mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 236, 1980.
human TDLo intravenous 40ug/kg/4D-I (0.04mg/kg) skin and appendages (skin): "dermatitis, other: after systemic exposure" New England Journal of Medicine. Vol. 281, Pg. 1094, 1969.
rat LD50 oral 7200ug/kg (7.2mg/kg) Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960.
rat LD50 subcutaneous 800ug/kg (0.8mg/kg) Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960.

  • Ewing's sarcoma

  • Gestational trophoblastic tumour

  • Neoplasm

  • Neoplasm malignant

  • Nephroblastoma

  • Rhabdomyosarcoma

  • Testis cancer

  • Diarrhoea (0.3)

  • Stomatitis (0.3)

    • 050A760 1-N,9-N-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide 15160-EP2272827A1
    15160-EP2275420A1 15160-EP2280012A2 15160-EP2281815A1
    15160-EP2289892A1 15160-EP2292615A1 15160-EP2295055A2
    15160-EP2295416A2 15160-EP2295426A1 15160-EP2295427A1
    15160-EP2298748A2 15160-EP2298764A1 15160-EP2298765A1
    15160-EP2301928A1 15160-EP2301933A1 15160-EP2305640A2
    15160-EP2305642A2 15160-EP2305671A1 15160-EP2308833A2
    15160-EP2311453A1 15160-EP2311808A1 15160-EP2311827A1
    15160-EP2311829A1 15160-EP2311842A2 15160-EP2316832A1
    15160-EP2316833A1 1CC1JFE158 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis-[(18aS)-10c,14,17-trimethyl-5,8,12,15,18-pentaoxo-6c,13t-di(propan-2-yl)-18ar-hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-9c-yl]-3H-phenoxazine-1,9-dicarboxamide
    2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide 2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide 2-amino-4,6-dimethyl-3-oxo-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
    2-amino-N,N''''''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide 2-amino-N,N''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide 2-amino-N,N''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide
    2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide 2-amino-N1,N9-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-phenoxazine-1,9-dicarboxamide 2-azanyl-4,6-dimethyl-3-oxidanylidene-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentakis(oxidanylidene)-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
    3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo- 50-76-0 AB00514445-05
    ACT D ACT [antibiotic] ACTINOMYCIN-D
    AD (VAN) AI3-26374 AKOS030228553
    ActD Actactinomycin A IV Actinomycin 7
    Actinomycin Aiv Actinomycin C(sub1) Actinomycin C1
    Actinomycin D, for fluorescence, >=90% (HPLC), from Streptomyces sp. Actinomycin D, from Streptomyces sp., >=95% (HPLC) Actinomycin D, from Streptomyces sp., suitable for cell culture, >=95%
    Actinomycin D, from Streptomyces sp., ~98% (HPLC) Actinomycin IV Actinomycin X 1
    Actinomycin-(threo-val-pro-sar-meval) Actinomycindioic D acid, dilactone Acto-D
    Antibiotic from Streptomyces parvullus BDBM43866 BDBM50089528
    BRD-K70578146-001-01-8 BRD-K70578146-001-04-2 CAS-50-76-0
    CCG-101134 CHEBI:27666 CHEMBL1554
    CHEMBL3792960 CPD000469227 CTK8F7580
    Cosmegen Cosmegen Lyovac DACTINOMYCIN
    DB00970 DSSTox_CID_31 DSSTox_GSID_20031
    DSSTox_RID_75330 DTXSID9020031 Dactinomicina
    Dactinomicina [INN-Spanish] Dactinomycin D Dactinomycin [USAN:USP:INN:BAN]
    Dactinomycin, United States Pharmacopeia (USP) Reference Standard Dactinomycine Dactinomycine [INN-French]
    Dactinomycinum Dactinomycinum [INN-Latin] Dilactone actinomycin D acid
    Dilactone actinomycindioic D acid EINECS 200-063-6 FT-0080366
    GNF-PF-1977 GNF-Pf-2290 Glycopeptide, 4a
    HMS2052O17 Lyovac cosmegen Lyovac-Cosmegen
    MFCD00005033 MLS001424196 Meractinomycin
    NC00384 NCGC00090796-01 NCGC00161622-01
    NCGC00161622-02 NCGC00260031-01 NCGC00271789-02
    NCI-C04682 NSC 3053 NSC3053
    Oncostatin K Q186127 RJURFGZVJUQBHK-IIXSONLDSA-N
    SAM001246846 SCHEMBL3844 SMR000469227
    SR-01000763161 SR-01000763161-4 Specific stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)-bis(carbonylimino(2-hydroxypropylidene)carbonyliminoisobutylidenecarbonyl-1,2-pyrrolidinediylcarbonyl(methylimino)methylenecarbonyl))bis(N-methyl-L-valine) dilactone
    Stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)bis(carbonylimino(2-(1-hydroxyethyl)-1-oxo-2,1-ethanediyl)imino(2-(1-methylethyl)-1-oxo-2,1-ethanediyl)-1,2-pyrrolidinediylcarbonyl(methylimino) (1-oxo-2,1-ethanediyl)))bis(N-methyl-L-valine)di-xi-lactone Tox21_111997 Tox21_111997_1
    Tox21_202482 UNII-0OCC969V50 component RJURFGZVJUQBHK-IIXSONLDSA-N UNII-1CC1JFE158
    UPCMLD-DP055 UPCMLD-DP055:001 UPCMLD-DP055:002
    X 97 actinomycin D cid_457193

    DrugBank Name Dactinomycin
    DrugBank DB00970
    CAS Number 50-76-0
    PubChem Compound 457193
    KEGG Compound ID C06770
    KEGG Drug D00214
    ChEBI 27666
    PharmGKB PA151917012
    ChemSpider 10482167
    Wikipedia Dactinomycin